| (Values in U.S. Thousands) | Mar, 2023 | Mar, 2022 | Mar, 2021 | Mar, 2020 | Mar, 2019 |
| Sales | 7,546 | 8,539 | 8,735 | 9,819 | 8,757 |
| Sales Growth | -11.63% | -2.24% | -11.04% | +12.13% | -35.39% |
| Net Income | -3,860 | -11,333 | -2,104 | -6,828 | 974 |
| Net Income Growth | +65.94% | -438.56% | +69.18% | -800.88% | +113.40% |
Omega Diagnostics Group Plc (ODX.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Omega Diagnostics Group PLC provides in-vitro diagnostics (IVD) products for use in hospitals, blood banks, clinics and laboratories and specializes in the areas of allergy and autoimmune, food intolerance and infectious diseases. The company's segment includes Health and Nutrition and Corporate. It generates maximum revenue from the Health and Nutrition segment. The Health and Nutrition division specializes in the research, development, and production of kits to aid the detection of immune reactions to food. Geographically, it derives a majority of its revenue from Rest of Europe.